Cargando…

Foreword to ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’

Detalles Bibliográficos
Autor principal:	Paz-Ares, Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735209/ https://www.ncbi.nlm.nih.gov/pubmed/33293669 http://dx.doi.org/10.1038/s41416-020-01068-0

Ejemplares similares

Summary of ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’
por: Paz-Ares, Luis
Publicado: (2020)

The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management
por: Denault, Marie-Helene, et al.
Publicado: (2023)

Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment
por: Agbarya, Abed, et al.
Publicado: (2022)

Current status and future directions in unresectable stage III non-small cell lung cancer
por: Arellano, Esperanza Arriola, et al.
Publicado: (2020)

Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?
por: Remon, Jordi, et al.
Publicado: (2022)

Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives
por: Middleton, Mark R., et al.
Publicado: (2020)

Foreword: Current Perspectives in Acid Inhibitory Therapy
por: Modlin, Irvin M.
Publicado: (1996)

Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy
por: Lau, Sally C.M., et al.
Publicado: (2021)

IDO1 Activity Predicts Lung Toxicity in Patients with Unresectable Stage III NSCLC and Chemoradiotherapy
por: Wu, Linfang, et al.
Publicado: (2023)

The current treatment landscape in the UK for stage III NSCLC
por: Evison, Matthew
Publicado: (2020)

Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy
por: Wu, Linfang, et al.
Publicado: (2022)

Follow-Up Imaging Guidelines for Patients with Stage III Unresectable NSCLC: Recommendations Based on the PACIFIC Trial
por: Ko, Jenny J., et al.
Publicado: (2023)

Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective
por: Dunlop, Will, et al.
Publicado: (2021)

Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC
por: Zhao, Qianqian, et al.
Publicado: (2019)

Treatment Patterns for Patients With Unresected Stage III NSCLC: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database
por: Shang, Shijie, et al.
Publicado: (2022)

Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects
por: Peters, Solange, et al.
Publicado: (2022)

Foreword: Focus on complex metallic phases
por: Shechtman, Dan
Publicado: (2014)

Management of Unresectable Localized Pelvic Bone Sarcomas: Current Practice and Future Perspectives
por: Soares do Brito, Joaquim, et al.
Publicado: (2022)

Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients with locally advanced, unresectable, stage Ⅲ nsclc in china
por: Jiang, Xiaotong, et al.
Publicado: (2022)

Foreword
por: Frieman, Matt, et al.
Publicado: (2015)

Foreword
por: Mínguez, Beatriz, et al.
Publicado: (2022)

Foreword
por: Enjuanes, Luis, et al.
Publicado: (2014)

Unresectable hepatoblastoma: current perspectives
por: Trobaugh-Lotrario, Angela D, et al.
Publicado: (2017)

Neoadjuvant Immuno-Chemotherapy: A New Perspective for Stage III NSCLC?
por: Yao, Yuanshan, et al.
Publicado: (2022)

A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China
por: Li, Wei, et al.
Publicado: (2023)

The cost of unresectable stage III or stage IV melanoma in Italy
por: Maio, Michele, et al.
Publicado: (2012)

Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours
por: Naito, Yoichi, et al.
Publicado: (2023)

Correction to: Foreword
por: Mínguez, Beatriz, et al.
Publicado: (2022)

Correction to: Foreword
por: Mínguez, Beatriz, et al.
Publicado: (2022)

Elevated neutrophil‐to‐lymphocyte ratio (NLR) is associated with poorer progression‐free survival in unresectable stage III NSCLC treated with consolidation durvalumab
por: Nindra, Udit, et al.
Publicado: (2022)

Metabolic patterns on [(18)F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment
por: Holzgreve, Adrien, et al.
Publicado: (2023)

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
por: Gray, Jhanelle E., et al.
Publicado: (2019)

Paradigm Shift in the Treatment of Elderly Patients With Unresectable Stage IV Colorectal Cancer
por: Kim, Nam Kyu
Publicado: (2014)

Durvalumab in NSCLC: latest evidence and clinical potential
por: Muñoz-Unceta, Nerea, et al.
Publicado: (2018)

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
por: Hotta, Katsuyuki, et al.
Publicado: (2020)

Foreword: Current Laboratory Aspects of COVID-19
por: Nagy, Béla
Publicado: (2022)

Foreword
por: González-Vílchez, Francisco
Publicado: (2000)

Foreword
por: Richards, M A
Publicado: (2008)

Foreword
Publicado: (2000)

Foreword
por: Freed, W. J.
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_951gl1bvmeh2ptcgrh4jasi676